In a strategic move to fortify its global presence and enhance pharmaceutical production capabilities, Boehringer Ingelheim, the pharmaceutical giant, has announced the further expansion and upgrade of its production site in Koropi, Greece.
With an investment of 120 million euros, Boehringer Ingelheim is set out to increase its manufacturing capacities for new and existing drugs, showing its commitment to advancing healthcare solutions and underscoring the importance of the Greek site in its global manufacturing network.
The main areas involved include cardio-renal-metabolic diseases, pulmonary fibrosis, systemic sclerosis, chronic liver, and mental health, with many products that are already in the late stage of their clinical development. Thanks to this expansion, the company will create 110 new jobs and boost its exports from Greece to the US market.
The Expansion Plan
Boehringer Ingelheim’s expansion plan for the Koropi site encompasses both scale and sophistication. The investment aims to bolster production capacity and modernize facilities, aligning with the pharmaceutical industry’s evolving needs and standards. The strategic decision to expand in Greece reflects the country’s strategic importance as a key player in the pharmaceutical manufacturing landscape.
The boost to the local economy and employment is highlighted by the Greek Prime Minister, Kyriakos Mitsotakis, who attended the groundbreaking ceremony at the Koropi site: “I am delighted to once again visit this plant which, as we have heard, produces some of the most innovative antidiabetic medicines, and to see the excellent organization as well as the high level of expertise and professionalism of the staff. I am also very pleased with the progress that the company has made; with the 700 skilled employees whose number will increase by more than 100 when this investment is completed; and, of course, with this important shift towards innovation. I want to thank the company for its continuous trust in Greece.”
Historical Significance of Koropi Site:
The Koropi production site has long played a pivotal role in Boehringer Ingelheim’s global operations. Located in the vicinity of Athens, this site has been a hub for the production of various pharmaceutical products, contributing significantly to the company’s commitment to innovation, quality, and patient well-being.
The history of the pharmaceutical giant in Greece is well remembered by Hubertus von Baumbach, Chairman of the Board of Managing Directors at Boehringer Ingelheim: “We have been present in Greece since 1966, and have gradually expanded our operations in the country. This expansion investment will bring some of our most innovative therapies to an increasing number of patients globally.”
The expansion further strengthens the presence of the company in the country.